300 related articles for article (PubMed ID: 31465135)
1. Constrained Nanoparticles Deliver siRNA and sgRNA to T Cells In Vivo without Targeting Ligands.
Lokugamage MP; Sago CD; Gan Z; Krupczak BR; Dahlman JE
Adv Mater; 2019 Oct; 31(41):e1902251. PubMed ID: 31465135
[TBL] [Abstract][Full Text] [Related]
2. Nanoparticles That Deliver RNA to Bone Marrow Identified by in Vivo Directed Evolution.
Sago CD; Lokugamage MP; Islam FZ; Krupczak BR; Sato M; Dahlman JE
J Am Chem Soc; 2018 Dec; 140(49):17095-17105. PubMed ID: 30394729
[TBL] [Abstract][Full Text] [Related]
3. Analyzing 2000 in Vivo Drug Delivery Data Points Reveals Cholesterol Structure Impacts Nanoparticle Delivery.
Paunovska K; Gil CJ; Lokugamage MP; Sago CD; Sato M; Lando GN; Gamboa Castro M; Bryksin AV; Dahlman JE
ACS Nano; 2018 Aug; 12(8):8341-8349. PubMed ID: 30016076
[TBL] [Abstract][Full Text] [Related]
4. Structure, activity and uptake mechanism of siRNA-lipid nanoparticles with an asymmetric ionizable lipid.
Suzuki Y; Ishihara H
Int J Pharm; 2016 Aug; 510(1):350-8. PubMed ID: 27374199
[TBL] [Abstract][Full Text] [Related]
5. High-throughput in vivo screen of functional mRNA delivery identifies nanoparticles for endothelial cell gene editing.
Sago CD; Lokugamage MP; Paunovska K; Vanover DA; Monaco CM; Shah NN; Gamboa Castro M; Anderson SE; Rudoltz TG; Lando GN; Munnilal Tiwari P; Kirschman JL; Willett N; Jang YC; Santangelo PJ; Bryksin AV; Dahlman JE
Proc Natl Acad Sci U S A; 2018 Oct; 115(42):E9944-E9952. PubMed ID: 30275336
[TBL] [Abstract][Full Text] [Related]
6. Enhanced Delivery of siRNA to Retinal Ganglion Cells by Intravitreal Lipid Nanoparticles of Positive Charge.
Huang X; Chau Y
Mol Pharm; 2021 Jan; 18(1):377-385. PubMed ID: 33295773
[TBL] [Abstract][Full Text] [Related]
7. Piperazine-derived lipid nanoparticles deliver mRNA to immune cells in vivo.
Ni H; Hatit MZC; Zhao K; Loughrey D; Lokugamage MP; Peck HE; Cid AD; Muralidharan A; Kim Y; Santangelo PJ; Dahlman JE
Nat Commun; 2022 Aug; 13(1):4766. PubMed ID: 35970837
[TBL] [Abstract][Full Text] [Related]
8. Hydrophobic scaffolds of pH-sensitive cationic lipids contribute to miscibility with phospholipids and improve the efficiency of delivering short interfering RNA by small-sized lipid nanoparticles.
Sato Y; Okabe N; Note Y; Hashiba K; Maeki M; Tokeshi M; Harashima H
Acta Biomater; 2020 Jan; 102():341-350. PubMed ID: 31733331
[TBL] [Abstract][Full Text] [Related]
9. Neutralization of negative charges of siRNA results in improved safety and efficient gene silencing activity of lipid nanoparticles loaded with high levels of siRNA.
Sato Y; Matsui H; Sato R; Harashima H
J Control Release; 2018 Aug; 284():179-187. PubMed ID: 29936118
[TBL] [Abstract][Full Text] [Related]
10. Effect of the nanoformulation of siRNA-lipid assemblies on their cellular uptake and immune stimulation.
Kubota K; Onishi K; Sawaki K; Li T; Mitsuoka K; Sato T; Takeoka S
Int J Nanomedicine; 2017; 12():5121-5133. PubMed ID: 28790820
[TBL] [Abstract][Full Text] [Related]
11. The development of an in vitro assay to screen lipid based nanoparticles for siRNA delivery.
Zhang Y; Arrington L; Boardman D; Davis J; Xu Y; DiFelice K; Stirdivant S; Wang W; Budzik B; Bawiec J; Deng J; Beutner G; Seifried D; Stanton M; Gindy M; Leone A
J Control Release; 2014 Jan; 174():7-14. PubMed ID: 24240015
[TBL] [Abstract][Full Text] [Related]
12. Investigating impacts of surface charge on intraocular distribution of intravitreal lipid nanoparticles.
Huang X; Chau Y
Exp Eye Res; 2019 Sep; 186():107711. PubMed ID: 31238078
[TBL] [Abstract][Full Text] [Related]
13. A Combinatorial Library of Lipid Nanoparticles for RNA Delivery to Leukocytes.
Ramishetti S; Hazan-Halevy I; Palakuri R; Chatterjee S; Naidu Gonna S; Dammes N; Freilich I; Kolik Shmuel L; Danino D; Peer D
Adv Mater; 2020 Mar; 32(12):e1906128. PubMed ID: 31999380
[TBL] [Abstract][Full Text] [Related]
14. Development of a Microfluidic-Based Post-Treatment Process for Size-Controlled Lipid Nanoparticles and Application to siRNA Delivery.
Kimura N; Maeki M; Sato Y; Ishida A; Tani H; Harashima H; Tokeshi M
ACS Appl Mater Interfaces; 2020 Jul; 12(30):34011-34020. PubMed ID: 32667806
[TBL] [Abstract][Full Text] [Related]
15. Understanding structure-activity relationships of pH-sensitive cationic lipids facilitates the rational identification of promising lipid nanoparticles for delivering siRNAs in vivo.
Sato Y; Hashiba K; Sasaki K; Maeki M; Tokeshi M; Harashima H
J Control Release; 2019 Feb; 295():140-152. PubMed ID: 30610950
[TBL] [Abstract][Full Text] [Related]
16. pH-labile PEGylation of siRNA-loaded lipid nanoparticle improves active targeting and gene silencing activity in hepatocytes.
Hashiba K; Sato Y; Harashima H
J Control Release; 2017 Sep; 262():239-246. PubMed ID: 28774839
[TBL] [Abstract][Full Text] [Related]
17. Lipid Nanoparticle Formulations for Enhanced Co-delivery of siRNA and mRNA.
Ball RL; Hajj KA; Vizelman J; Bajaj P; Whitehead KA
Nano Lett; 2018 Jun; 18(6):3814-3822. PubMed ID: 29694050
[TBL] [Abstract][Full Text] [Related]
18. Nanoparticles containing constrained phospholipids deliver mRNA to liver immune cells in vivo without targeting ligands.
Gan Z; Lokugamage MP; Hatit MZC; Loughrey D; Paunovska K; Sato M; Cristian A; Dahlman JE
Bioeng Transl Med; 2020 Sep; 5(3):e10161. PubMed ID: 33758781
[TBL] [Abstract][Full Text] [Related]
19. Development of Lipidoid Nanoparticles for siRNA Delivery to Neural Cells.
Khare P; Dave KM; Kamte YS; Manoharan MA; O'Donnell LA; Manickam DS
AAPS J; 2021 Dec; 24(1):8. PubMed ID: 34873640
[TBL] [Abstract][Full Text] [Related]
20. Polydispersity characterization of lipid nanoparticles for siRNA delivery using multiple detection size-exclusion chromatography.
Zhang J; Haas RM; Leone AM
Anal Chem; 2012 Jul; 84(14):6088-96. PubMed ID: 22816783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
